Viking Therapeutics Inc（VKTX）の財務VKTXViking Therapeutics Inc

Evaluating the bottom line, Viking Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -88.85%, provide a clear picture of how effectively VKTX converts its operational activities into shareholder value.

In the context of the broader market, VKTX competes directly with industry leaders such as IDYA and XENE. With a market capitalization of $3.10B, it holds a significant position in the sector. When comparing efficiency, VKTX's gross margin of N/A stands against IDYA's 100.00% and XENE's N/A. Such benchmarking helps identify whether Viking Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Viking Therapeutics has shown significant losses, with net income projected to decline to -$158.3 million in Q1 2026. The current ratio has also decreased from 33.09 in Q4 2024 to 4.72 in Q2 2026, indicating worsening liquidity.